Flag of the European Union EU Clinical Trials Register Help

Clinical trials for alk abello

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: alk abello. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2005-005636-28 Sponsor Protocol Number: E04/05/PP-M Start Date*: 2006-08-29
    Sponsor Name:ALK-ABELLÓ, S.A.
    Full Title: Valoración de la eficacia a corto plazo de un extracto de Dermatophagoides pteronyssinus, valorado en unidades de masa y administrado por vía subcutánea, en el tratamiento del asma alérgico. Estudi...
    Medical condition: Asma alérgico perenne, con/sin síntomas de rinitis o rinoconjuntivitis, por sensibilización a Dermatophagoides pteronyssinus.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-000492-32 Sponsor Protocol Number: T16/2013 Start Date*: 2013-07-10
    Sponsor Name:Turku University Hospital
    Full Title: T cell and interferon expression in tonsils after sublingual immunotherapy and/or nasal live attenuated influenza vaccine
    Medical condition: We investigate the effects of allergen and virus on patients with recurrent tonsillitis or tonsillar hypertrphy.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003732-72 Sponsor Protocol Number: 13IC0847 Start Date*: 2013-10-14
    Sponsor Name:Imperial College London
    Full Title: Randomised placebo-controlled study of grass pollen allergen immunotherapy tablet (AIT) for seasonal rhinitis: time course of nasal, cutaneous and immunological outcomes
    Medical condition: Grass-pollen induced rhinoconjunctivitis (hay fever).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-015381-64 Sponsor Protocol Number: CRI-2009-09-001-IV Start Date*: 2009-11-16
    Sponsor Name:Clinical Research International Ltd.
    Full Title: "3D-Visualization of the anti-obstructive effect of Levocetirizine"
    Medical condition: patient with seasonal allergic rhinitis caused by pollen-allergens
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001726 Allergic rhinitis due to pollen LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005092-14 Sponsor Protocol Number: GT-24 Start Date*: 2013-03-12
    Sponsor Name:ALK-Abelló S.A.
    Full Title: Molecular and Cellular Mechanism in the course of Immunotherapy with a Phleum pratense oral lyophilisate
    Medical condition: Treatment of grass pollen induced rhinitis and conjunctivitis in adult patients with clinically relevant symptoms and diagnosed witha positive skin-prick test and / or specific IgE test to grass po...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004855 10001726 Allergic rhinitis due to pollen LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001795-20 Sponsor Protocol Number: MT-02 Start Date*: 2006-06-29
    Sponsor Name:ALK-Abelló A/S
    Full Title: A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic subjects
    Medical condition: IgE mediated House dust mite induced mild to moderate asthma and mild to severe allergic rhinitis.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) DK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000560-22 Sponsor Protocol Number: MT-12 Start Date*: Information not available in EudraCT
    Sponsor Name:ALK-Abelló A/S
    Full Title: A one-year placebo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivi...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis induced by house dust mites
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) SK (Completed) DE (Completed) PL (Completed) ES (Ongoing) BG (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000446-34 Sponsor Protocol Number: MT-18 Start Date*: 2020-07-14
    Sponsor Name:ALK-Abelló A/S
    Full Title: A 28-day, single-armed, open-label trial to evaluate safety of the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in adolescent subjects (12-17 years of age) with HDM allergic...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis induced by house dust mite
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-002461-37 Sponsor Protocol Number: PEPITES Start Date*: 2015-12-17
    Sponsor Name:DBV Technologies
    Full Title: A double-blind, placebo-controlled, randomized phase III pivotal trial to assess the efficacy and safety of peanut epicutaneous immunotherapy with viaskin peanut in peanut-allergic children
    Medical condition: Peanut Allergy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002916-42 Sponsor Protocol Number: PEOPLE-V712-303 Start Date*: Information not available in EudraCT
    Sponsor Name:DBV TECHNOLOGIES S.A.
    Full Title: Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin® Peanut (PEOPLE Study)
    Medical condition: Peanut Allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011453-41 Sponsor Protocol Number: GT-20 Start Date*: 2009-09-17
    Sponsor Name:ALK-Abelló S.A.
    Full Title: Mecanismos moleculares y celulares de rinitis alérgica en pacientes tratados con GRAZAX® -"Molecular and cellular mechanism in rhinitis allergic patients treated with GRAZAX®"
    Medical condition: Tratamiento de la rinitis y conjuntivitis inducida por polen de gramíneas en pacientes adultos con síntomas clínicamente relevantes y diagnosticados mediante prueba cutánea de prick positiva y/o te...
    Disease: Version SOC Term Classification Code Term Level
    9 10001726 Allergic rhinitis due to pollen LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005823-35 Sponsor Protocol Number: 20201206 Start Date*: 2021-01-28
    Sponsor Name:Aarhus Universitet [...]
    1. Aarhus Universitet
    2. Aarhus Universitet
    3. Aarhus Universitet
    4. Aarhus Universitet
    Full Title: ILIT.FT – Dose finding for intralymphatic allergen immunotherapy in a randomized, parallel group, double blind placebo-controlled field trial
    Medical condition: Allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003456-20 Sponsor Protocol Number: ITN084AD Start Date*: 2020-02-17
    Sponsor Name:Division of Allergy, Immunology, and Transplantation; National Institute of Allergy and Infectious Disease
    Full Title: Grass Pollen Sublingual Tablet Immunotherapy plus Dupilumab for Induction of Tolerance in Adults with Moderate to Severe Seasonal Allergic Rhinitis.
    Medical condition: Moderate to Severe Seasonal Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-013429-40 Sponsor Protocol Number: CVAK694A2205 Start Date*: 2009-10-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Randomized, double-blind, placebo-controlled trial to determine the capacity of VAK694 to elicit long term immune tolerance when combined with subcutaneous allergen immunotherapy for the treatment ...
    Medical condition: Seasonal allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001662-94 Sponsor Protocol Number: TH005 Start Date*: 2014-09-16
    Sponsor Name:Circassia Ltd.
    Full Title: A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects with a History of House Dust Mite-Induced Rhinoconjunctivitis
    Medical condition: House Dust Mite-Induced Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) NL (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2012-001733-13 Sponsor Protocol Number: CP007 Start Date*: 2012-10-04
    Sponsor Name:Circassia Limited
    Full Title: A Double Blind, Randomised, Placebo Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
    Medical condition: Treatment of cat allergen induced rhinoconjunctivitis in patients with clinically relevant symptoms
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed) BE (Completed) CZ (Completed) DE (Completed) HU (Completed) SK (Completed) LT (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011235-12 Sponsor Protocol Number: GT-21 Start Date*: 2009-10-30
    Sponsor Name:ALK-Abelló A/S
    Full Title: GAP Grazax Asthma Prevention
    Medical condition: To prevent development of asthma - The aim of the trial is to investigate whether three consecutive years of treatment with Grazax (75.000 SQ-T) reduces the risk of developing asthma in children co...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10003553 Asthma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) FI (Completed) DK (Completed) GB (Completed) SE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000196-23 Sponsor Protocol Number: SLO-AD-1 Italy Start Date*: 2008-10-14
    Sponsor Name:ALK-ABELLO'
    Full Title: Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild-to-moderate atopic eczema (AE) and sensitization to HDM (SPT positive).
    Medical condition: Moderate/severe persistent Atopic Eczema (SCORAD >8 and <40)in patients sentitized to HDM
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040785 SOC
    9.1 10038738 SOC
    9.1 10021428 SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019373-15 Sponsor Protocol Number: 291202BS Start Date*: 2010-06-15
    Sponsor Name:Marinomed Biotechnologie GmbH
    Full Title: A phase IIa, single-center, randomized, reference-controlled, observer-blind trial to assess the efficacy of a topical Aescin formulation in experimentally induced itch, wheal and flare reactions i...
    Medical condition: subjects with proven type I allergy against one of the three allergens: grass pollen, tree pollen, cat epithelia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036019 Pollen allergy LLT
    12.1 10066093 Birch pollen allergy LLT
    12.1 10001742 Allergy to animal LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001060-28 Sponsor Protocol Number: 2020-001060-28 Start Date*: 2021-03-16
    Sponsor Name:Aarhus Universitet
    Full Title: Documentation of efficacy for intralymphatic allergen immunotherapy in a phase III randomized, parallel group, double blind placebo-controlled multisite field trial
    Medical condition: Allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:04:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA